Gilead Widens Royalty-Free Lenacapavir Licensing to 120 Countries

RegulationProduct / Tech
โดย Simply Wall St·GLOBAL·Read original
Summary · why it matters

Gilead Sciences has expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group also signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean, creating a direct pathway for 14 additional countries in the region to obtain the drug for HIV prevention programs. The expanded royalty-free licenses and the PAHO agreement tilt Gilead further toward a volume-based access model in HIV prevention, particularly in low and lower middle income markets, with partners such as Dr. Reddy's and Hetero expected to handle much of the production and local distribution. The company said the clearest test over the next couple of years will be whether countries move from agreements to funded rollouts, especially as Phase 3 PURPOSE 365 data matures and PAHO's revolving funds translate into concrete procurement. Uptake in the 14 additional Latin American and Caribbean markets outside the core licensing pool will be a particularly useful early signal.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 1 stocks
Health Care▲ · 1 stocks

Theme Impact 1

Related news

▲

Chiome Bioscience's Influenza Antibody Research Paper Published in International Academic Journal

Chiome Bioscience announced that the results of joint research with a research group from the Infectious Pathology Division of the National Institute of Infectious Diseases at the National Center for Global Health and Medicine has been published in the international academic journal Protein Science. In the study, the researchers designed a unique antigen targeting influenza virus that utilizes molecular mimicry by anti-idiotype antibodies, and showed that it can induce antibodies in inoculated animals that react broadly to multiple types of the virus. Following the announcement, shares of Chiome Bioscience widened their gains in the afternoon session and are currently at 94 yen, up 6 yen from the previous day.
4583.JP ▲
Biotech & Genomic Medicine ▲
トレーダーズ・ウェブ·3dRead more →

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Sunshine Biopharma Inc. has advanced its lead Coronavirus drug candidate into IND-enabling studies, the company announced. The nominated compound, a PLpro protease inhibitor, showed nanomolar potency against the viral protease and broad-spectrum activity against SARS-CoV-2 variants of concern in vitro, with high oral bioavailability in mice, rats and dogs and preferential enrichment in the lungs of mice and rats. In K18-hACE2 mice infected with human SARS-CoV-2, repeated oral administrations significantly suppressed pulmonary viral replication in a dose-dependent manner. CEO Dr. Steve Slilaty called the advance a strategically significant development and a validation of the company's discovery infrastructure, adding that the program is being accelerated with regulatory discipline. The company previously published laboratory results on its anti-coronavirus compound library in August 2024 and March 2026 in the Journal of Medicinal Chemistry. Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled for launch in the remainder of 2026.
SBFM ▲
Biotech & Genomic Medicine
Sunshine Biopharma Inc.·4dRead more →
▲

Gilead Wins Fourth Circuit Ruling Blocking Imported HIV Drug Sales

A federal appeals court ruled in favor of Gilead Sciences on August 13, upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the United States. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were material, not theoretical. The dispute dates to December 2024, when Gilead sued third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy over illegal imports of its best-selling HIV drug Biktarvy, a case that arose after a patient in Maryland received the medicine by mail from Turkey with label instructions written in Turkish. A federal district court in Baltimore granted the preliminary injunction after finding Gilead likely to succeed on its Lanham Act trademark violation and unfair competition arguments, and the order was later expanded to include new sellers CanaRx, ElectRx, and ScriptSourcing. The Fourth Circuit rejected the defendants' central argument that the imported and domestic versions of Biktarvy are interchangeable, holding that the two differ materially not only in packaging and labeling but also in the quality-control protocols each version undergoes before reaching a patient. A Gilead representative called the decision a patient-safety victory, and patient advocacy groups that filed amicus briefs supporting the company praised the ruling in similar terms.
GILD ▲
Biotech & Genomic Medicine ▲
Insider Monkey·8dRead more →
© 2026 MarketDXNews